^
    2years
    Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics. (PubMed, Molecules)
    The obtained conjugates have increased water solubility for systemic delivery in the blood and prevent cell penetrance and, thus, killing until the TG-prodrug is hydrolyzed by the targeting protease in the vicinity of the cancer cells. We summarize the preclinical validation of each of these TG-prodrugs with special attention to the PSMA TG-prodrug, Mipsagargin, which is in phase II clinical testing.
    Review • Journal
    |
    FOLH1 (Folate hydrolase 1) • FAP (Fibroblast activation protein, alpha) • KLK2 (Kallikrein-related peptidase 2) • KLK3 (Kallikrein-related peptidase 3)
    |
    mipsagargin (G-202)
    over3years
    Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer. (PubMed, Transl Oncol)
    Apatinib showed promising efficacy and an acceptable safety profile in patients with advanced AFPGC. Antiangiogenic therapy may be a good strategy for the treatment of AFPGC as a rare sub-type of gastric cancer.
    Clinical • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • AFP (Alpha-fetoprotein)
    |
    AiTan (rivoceranib) • mipsagargin (G-202)
    4years
    Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202). (PubMed, Am J Cancer Res)
    We found heavily pretreated advanced gastric cancer patients can tolerate and benefit from lower-doses of apatinib therapy. The lower initial daily dosing strategy represents an alternative approach for optimizing apatinib dosing in clinical practice.
    Clinical • Journal • Real-World Evidence
    |
    KDR (Kinase insert domain receptor)
    |
    AiTan (rivoceranib) • mipsagargin (G-202)